G. Uccello-Barretta et al. / Bioorg. Med. Chem. 12 (2004) 447–458
457
C14H18BrNO4S: calcd C, 44.69; H, 4.82; N, 3.72.
Found: C, 44.51; H, 4.83; N, 3.58.
(Department of Medicinal Chemistry & Institute for
Structural Biology and Drug Discovery, Virginia Com-
monwealth University, Richmond, Va Usa) have pro-
vided valuable discussion on the softwares GRID21 and
HINT2.35S (Sybyl 6.9 version), respectively. Schro-
dinger, Inc.22 is gratefully acknowledged for the soft-
ware Jaguar v.4.0 release 23. Toughtful advices by Prof.
A. Corsaro (Department of Chemistry, University of
Catania, Italy) and the support service of the Cam-
bridge Structural Database (CSD) were appreciated.
This work was supported by the Ministero della Ricerca
Scientifica e Tecnologica (MURST) and CNR, Italy.
3.2.1. Synthesis of trans-N-{4-[N0-(4-chlorobenzoyl)hy-
drazinocarbonyl]cyclohexylmethyl} - 4 - bromobenzenesul-
fonamide (G). A mixture of 3 (0.8 g, 2.00 mmol) and
HOBT (0.3 g, 29 mmol) in dry CH2Cl2 (25 mL) at 0 ꢀC,
under N2, was treated with EDC (0.4 g, 2.29 mmol).
After 1 h at 0 ꢀC, 4-chlorobenzoic hydrazide 4 (0.4 g,
2.27 mmol) was added. The reaction was stirred at room
temperature for 24 h. The solvent was evaporated and
the residue was taken up with ethyl ether (20 mL) and
water (20 mL). The obtained precipitate was filtered and
washed with ethyl ether (5Â20 mL) and n-hexane (5Â20
mL) in order to obtain G as a white solid (yield: 68%;
References and notes
ꢀ
1
mp 272 C). H NMR (DMSO-d6, 300 MHz) chemical
shift data are reported in Table 1. 13C NMR (300 MHz,
DMSO-d6, 25 ꢀC) d 28.6, 29.3, 36.8, 42.1, 48.7, 126.1,
128.6, 128.7, 129.4, 131.4, 132.3, 136.7, 140.1, 164.7,
174.7. C21H23BrClN3O4S: calcd C, 47.69; H, 4.38; N,
7.95. Found: C, 47.78; H, 4.45; N, 8.05.
1. Inui, A. Trends Pharmacol. Sci. 1999, 20, 43.
2. Stamford, A. W.; Parker, E. M. Annu. Rep. Med. Chem.
1999, 34, 31.
3. Criscione, L.; Rigollier, P.; Batzl-Hartmann, C.; Rueger,
H.; Stricker-Krongrad, A.; Wyss, P.; Brunner, L.; White-
bread, S.; Yamaguchi, Y.; Gerald, C.; Heurich, R. O.;
Walker, M. W.; Chiesi, M.; Schilling, W.; Hofbauer,
K. G.; Levens, N. J. Clin. Invest. 1998, 102, 2136.
4. Youngman, M. A.; McNally, J. J.; Lovenberg, T. W.;
Reitz, A. B.; Willard, N. M.; Nepomuceno, D. H.; Wil-
son, S. J.; Crooke, J. J.; Rosenthal, D.; Vaidya, A. H.;
Dax, S. L. J. Med. Chem. 2000, 43, 346.
5. Nagaaki, S.; Toshiyuki, T.; Takunobu, S.; Yuji, H.; Aya,
S.; Masaaki, H.; Miki, S.; Katsumasa, N.; Yuko, K.;
Hidefumi, K.; Naoko, F.; Yasuyuki, I.; Akane, I.; Akio,
K.; Takehiro, F. J. Med. Chem. 2003, 46, 666.
6. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.;
Leeson, P. D. J. Med. Chem. 2003, 46, 1250.
3.3. Binding Assays
Binding assays for both receptors NPY1 and NPY5
were done as described by Duhault et al.59,60 In brief,
for the human Y1 receptor binding assay, using iodi-
nated Peptide YY (NEN), incubations were performed
at 30 ꢀC for 90 min with various competitors con-
centrations in Buffer A (Hepes/NaOH 20 mM, pH 7.4,
NaCl 10 mM, KH2PO4 220 mM, CaCl2 1.26 mM,
MgSO4 0.81 mM and bovine serum albumin 0.1%) with
SKN-MC cell membranes (50 mg of protein/mL of
assay) in a total volume of 500 mL. Non-specific bind-
ing was determined in the presence of 1 mM NPY.
7. Ventura, C. A.; Fresta, M.; Paolino, D.; Pedotti, S.; Cor-
saro, A.; Puglisi, G. J. Drug Target 2001, 9, 379 (and
references cited therein).
8. Grigera, J. R.; Caffarena, E. R.; de Rosa, S. Carbohydr.
Res. 1998, 310, 253.
9. Goodford, P. J. J. Med. Chem. 1985, 28, 849.
10. Goodford, P. J. J. Chemometr. 1996, 10, 107.
11. Molecular Discovery Ltd.: West Way House, Elms Par-
ade, Oxford (www.moldiscovery.com).
12. Kellogg, G. E.; Abraham, D. J. Eur. J. Med. Chem. 2000,
35, 651 (www.edusoft-lc.com).
13. Cozzini, P.; Fornabaio, M.; Marabotti, A.; Abraham,
D. J.; Kellogg, G. E.; Mozzarelli, A. J. Med. Chem. 2002,
45, 2469.
14. SYBYL Molecular Modelling Software, version 6.8 and
6.9; Tripos Inc.: 1699 S-Hanley Rd, Suite 303, St. Louis,
MO 63144-2913, USA (www.tripos.com).
15. Cucinotta, V.; D’Alessandro, F.; Impellizzeri, G.; Vec-
chio, G. J. Chem. Soc., Chem. Commun. 1992, 23, 1743.
16. Cucinotta, V.; Giuffrida, A.; Grasso, G.; Maccarrone, G.;
Vecchio, G. J. Chromatogr. A 2001, 916, 61.
The reaction was then stopped by filtration, the filters
(GF/B, Whatman, precoated in 0.3% PEI) were exten-
sively washed with buffer A, and counted in a gamma
counter (Packard). For human Y5 receptor binding
assay, the binding was carried out with iodinated pep-
tide YY (NEN) as follows: COS cells transfected with
the human Y5 NPY receptor were lysed and the mem-
branes prepared by differential centrifugation. These
membranes contained about 2 pmol per mg of protein
of this receptor. Incubations were performed in 500 mL
comprising, 20 pM final of [125I]PYY in 50 mL, 400 mL
of membrane suspension (0.15 mg/mL) and competitor
dilutions in 50 mL, at 30 ꢀC for 2 h.
The reaction was stopped by filtration through GF/C
filters (Whatman).
17. Castro, E. A.; Barbiric, D. J. J. Arg. Chem. Soc. 2002, 90,
1.
18. Homer, J.; Perry, M. C. J. Chem. Soc., FaradayTrans. 1
1986, 82, 533.
Acknowledgements
19. Neuhaus, D.; Willianson, M. The Nuclear Overhauser
Effect; WCH: New York, 1989.
20. Valensin, G.; Kushnir, T.; Navon, G. J. Magn. Reson.
1982, 46, 23.
21. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Lis-
kamp, R.; Lipton, M.; Cauleld, C.; Chang, G.; Hen-
drickson, T.; Still, W. G. J. Comput. Chem. 1990, 11, 440.
22. Schrodinger, Inc.: 1500 S. W. First Avenue, Suite 1180
We are grateful to the Minnesota Supercomputing
Institute for providing computational resources in sup-
port of this work and Prof. C. J. Cramer (Department
of Chemistry and Supercomputer Institute, University
of Minnesota) for the helpful discussion on MIDI. Prof.
Peter J. Goodford (University of Oxford, Laboratory
of Molecular Biophysics) and Prof. E. G. Kellogg